Last reviewed · How we verify
mRNA-1273.214 Vaccine
mRNA-1273.214 Vaccine is a Biologic drug developed by Sheba Medical Center. It is currently in Phase 2 development.
At a glance
| Generic name | mRNA-1273.214 Vaccine |
|---|---|
| Sponsor | Sheba Medical Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (PHASE3)
- Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age (PHASE3)
- A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age (PHASE2, PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (PHASE2, PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 (PHASE2, PHASE3)
- COVID-19 Fourth Dose Study in Australia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-1273.214 Vaccine CI brief — competitive landscape report
- mRNA-1273.214 Vaccine updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI
Frequently asked questions about mRNA-1273.214 Vaccine
What is mRNA-1273.214 Vaccine?
mRNA-1273.214 Vaccine is a Biologic drug developed by Sheba Medical Center.
Who makes mRNA-1273.214 Vaccine?
mRNA-1273.214 Vaccine is developed by Sheba Medical Center (see full Sheba Medical Center pipeline at /company/sheba-medical-center).
What development phase is mRNA-1273.214 Vaccine in?
mRNA-1273.214 Vaccine is in Phase 2.
Related
- Manufacturer: Sheba Medical Center — full pipeline
- Compare: mRNA-1273.214 Vaccine vs similar drugs
- Pricing: mRNA-1273.214 Vaccine cost, discount & access